Montelukast

Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)

Condition:   AsthmaInterventions:   Drug: MK-1029 150 mg;   Drug: Placebo for MK-1029;   Drug: Montelukast 10 mg;   Drug: Albuterol/Salbutamol 90 mcg – 100 mcg per inhalationSponsor:   Merck Sharp & Dohme Corp.Not yet recruiting – verified March 2016 View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects

Condition:   Respiratory DisordersInterventions:   Drug: Reference Montelukast;   Drug: Test 1 Montelukast;   Drug: Test 2 MontelukastSponsor:   GlaxoSmithKlineNot yet recruiting – verified December 2014 View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Montelukast versus inhaled corticosteroids in the management of pediatric mild … – 7thSpace Interactive (press release)

Montelukast versus inhaled corticosteroids in the management of pediatric mild …7thSpace Interactive (press release)International guidelines recommend the use of inhaled corticosteroids (ICSs) as the preferred therapy, with leukotriene receptor antagonists (LTRAs) as an alternative, for the management of persistent asthma…

Patients with asthma or allergies initially prescribed montelukast instead of … – pharmabiz.com

Patients with asthma or allergies initially prescribed montelukast instead of …pharmabiz.comPatients with asthma or allergic rhinitis (nasal allergies), initially prescribed montelukast (Singulair) instead of typical first-line therapy have low rates of persistence on montelukast and may ultimately discontinue therapy altogether,…